{
    "name": "mavacamten",
    "comment": "Rx",
    "other_names": [
        "Camzyos"
    ],
    "classes": [
        "Cardiac Myosin Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/camzyos-mavacamten-4000214",
    "pregnancy": {
        "common": [
            "Based on animal data, may cause fetal harm when administered to pregnant females",
            "Human data are not available on use during pregnancy to evaluate for drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes",
            "Confirm absence of pregnancy in females of reproductive potential prior to initiation and use of effective contraception"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "Mavacamten-related decreases in mean fetal body weight, reductions in fetal ossification of bones, and increases in post-implantation loss (early and/or late resorptions) observed in rats and increases in visceral and skeletal malformations observed in both rabbits and rats at dose exposures like that achieved at maximum recommended human dose (MRHD)"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Advise females of reproductive potential to use effective contraception during treatment and for 4 months after last dose",
                    "Mavacamten may reduce effectiveness of combination hormonal contraceptives; advise using an alternant contraceptive method or add nonhormonal contraception"
                ]
            },
            {
                "type": "Clinical considerations",
                "description": [
                    "Underlying maternal condition during pregnancy poses risk to mother and fetus",
                    "Obstructive HCM in pregnancy associated with increased risk for preterm birth",
                    "Advise pregnant females about potential risk to fetus with maternal exposure to mavacamten during pregnancy"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Unknown if present in human or animal milk, effects on breastfed infants, and effects on milk production",
            "Consider developmental and health benefits of breastfeeding along with the motherâ€™s clinical need for mavacamten and any potential adverse effects on the breastfed child from the drug or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                " "
            ],
            "specific": [
                {
                    "type": "Risk of heart failure (HF)",
                    "description": [
                        "Reduces left ventricular ejection fraction (LVEF) and can cause HF owing to systolic dysfunction",
                        "ECG assessments of LVEF required before and during treatment",
                        "Initiation in patients with LVEF <55% not recommended",
                        "Interrupt dosing if LVEF <50% at any visit or if patient experiences HF symptoms or worsening clinical status",
                        "Coadministration with certain CYP450 inhibitors or discontinuation of certain CYP450 inducers may increase HF risk due to systolic dysfunction ",
                        "Available only through restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called Camzyos REMS Program; information available at www.camzyosrems.com or by telephone at 1-833-628-7367",
                        "Contraindicated with following",
                        "Moderate-to-strong CYP2C19 inhibitors or strong CYP3A4 inhibitors",
                        "Moderate-to-strong CYP2C19 or CYP3A4 inducers"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Coadministration with moderate-to-strong CYP2C19 inhibitors or strong CYP3A4 inhibitors",
                "Coadministration with moderate-to-strong CYP2C19 or CYP3A4 inducers "
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Only available through restricted REMS program requiring certification of prescribers and pharmacies, and enrollment of patients",
                "Based on animal studies, may cause fetal toxicity when administered to pregnant females; confirm absence of pregnancy in females of reproductive potential before initiating and instruct patient on use of effective contraception"
            ],
            "specific": [
                {
                    "type": "Heart failure",
                    "description": [
                        "Reduces systolic contraction and can cause HF or totally block ventricular function",
                        "Patients who experience a serious intercurrent illness (eg, serious infection) or arrhythmia (eg, atrial fibrillation, other uncontrolled tachyarrhythmia) are at greater risk of developing systolic dysfunction and HF",
                        "Patients should report any signs or symptoms of heart failure immediately to their healthcare provider ",
                        "Assess clinical status and LVEF before and regularly during treatment and adjust dose accordingly ",
                        "Promptly evaluate new or worsening arrhythmia, dyspnea, chest pain, fatigue, palpitations, leg edema, or elevations in N-terminal pro-B-type natriuretic peptide (NT-proBNP) as these may be signs and symptoms of HF",
                        "Asymptomatic LVEF reduction, intercurrent illnesses, and arrhythmias require additional dosing considerations",
                        "Initiation with LVEF <55% is not recommended"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Primarily metabolized by CYP2C19 and CYP3A4",
                        "Coadministration with drugs that interact with these enzymes may lead to life-threatening drug interactions (eg, heart failure) or loss of effectiveness",
                        "Advise patients of potential drug interactions, including OTC medications (eg, omeprazole, esomeprazole, or cimetidine)",
                        "Moderate-to-strong CYP2C19 or strong CYP3A4 inhibitors",
                        "Contraindicated",
                        "Coadministration with moderate-to-strong CYP2C19 inhibitors or strong CYP3A4 inhibitors increases mavacamten systemic exposure, which may increase risk of HF due to systolic dysfunction",
                        "Moderate-to-strong CYP2C19 or CYP3A4 inducers",
                        "Contraindicated",
                        "Coadministration with moderate-to-strong CYP2C19 or CYP3A4 inducers decreases mavacamten systemic exposure, which may reduce efficacy",
                        "May increase risk of adverse effects",
                        "Hormonal contraceptives",
                        "Use alternant contraceptive (eg, intrauterine system) not affected by CYP450 induction or add nonhormonal contraception during treatment and for 4 months after last dose",
                        "Progestin and ethinyl estradiol are CYP3A4 substrates",
                        "Mavacamten may decrease exposures of ethinyl estradiol and progestin, which may lead to contraceptive failure or increased breakthrough bleeding",
                        "Weak CYP2C19 or moderate CYP3A4 inhibitors",
                        "On stable therapy with weak CYP2C19 or moderate CYP3A4 inhibitor: Initiate at recommended 5 mg/day dose",
                        "Intend to initiate weak CYP2C19 or moderate CYP3A4 inhibitor: Reduce mavacamten dose by 1 level",
                        "On stable treatment with mavacamten 2.5 mg/day: Avoid initiating weak CYP2C19 or moderate CYP3A4 inhibitor (no lower mavacamten dose available)",
                        "Drugs that reduce cardiac contractility",
                        "Avoid coadministration",
                        "Coadministration with disopyramide in combination with verapamil or diltiazem has been associated with left ventricular systolic dysfunction and HF symptoms in patients with obstructive HCM",
                        "Avoid concomitant use in patients on disopyramide, ranolazine, verapamil with a beta blocker, or diltiazem with a beta blocker as these medications and combinations were excluded from the clinical study"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "abiraterone",
            "description": {
                "common": "abiraterone will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "amobarbital",
            "description": {
                "common": "amobarbital will decrease the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "armodafinil",
            "description": {
                "common": "armodafinil will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "belzutifan",
            "description": {
                "common": "belzutifan will decrease the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "bexarotene",
            "description": {
                "common": "bexarotene will decrease the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "bortezomib",
            "description": {
                "common": "bortezomib will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "bosentan",
            "description": {
                "common": "bosentan will decrease the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "butabarbital",
            "description": {
                "common": "butabarbital will decrease the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "butalbital",
            "description": {
                "common": "butalbital will decrease the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "cannabidiol",
            "description": {
                "common": "cannabidiol will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "cenobamate",
            "description": {
                "common": "cenobamate will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "chloramphenicol",
            "description": {
                "common": "chloramphenicol will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "clarithromycin will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "cobicistat",
            "description": {
                "common": "cobicistat will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "conivaptan",
            "description": {
                "common": "conivaptan will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "dabrafenib",
            "description": {
                "common": "dabrafenib will decrease the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "darunavir",
            "description": {
                "common": "darunavir will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "delavirdine",
            "description": {
                "common": "delavirdine will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "dexlansoprazole",
            "description": {
                "common": "dexlansoprazole will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "elagolix",
            "description": {
                "common": "elagolix will decrease the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "elvitegravir/cobicistat/emtricitabine/tenofovir DF will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "encorafenib",
            "description": {
                "common": "encorafenib decreases levels of mavacamten by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "enzalutamide",
            "description": {
                "common": "enzalutamide will decrease the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "eslicarbazepine acetate",
            "description": {
                "common": "eslicarbazepine acetate will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "esomeprazole",
            "description": {
                "common": "esomeprazole will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "etravirine",
            "description": {
                "common": "etravirine will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "fedratinib",
            "description": {
                "common": "fedratinib will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "fexinidazole will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "fluconazole",
            "description": {
                "common": "fluconazole will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "fluoxetine will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "fluvoxamine",
            "description": {
                "common": "fluvoxamine will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin will decrease the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "gemfibrozil",
            "description": {
                "common": "gemfibrozil will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "grapefruit",
            "description": {
                "common": "grapefruit will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "idelalisib",
            "description": {
                "common": "idelalisib will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "indinavir",
            "description": {
                "common": "indinavir will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "isoniazid",
            "description": {
                "common": "isoniazid will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "itraconazole",
            "description": {
                "common": "itraconazole will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ivosidenib",
            "description": {
                "common": "ivosidenib will decrease the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ketoconazole",
            "description": {
                "common": "ketoconazole will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lansoprazole",
            "description": {
                "common": "lansoprazole will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "levoketoconazole will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lonafarnib",
            "description": {
                "common": "lonafarnib will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lopinavir",
            "description": {
                "common": "lopinavir will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "loratadine",
            "description": {
                "common": "loratadine will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lorlatinib",
            "description": {
                "common": "lorlatinib will decrease the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lumacaftor/ivacaftor",
            "description": {
                "common": "lumacaftor/ivacaftor will decrease the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "mifepristone",
            "description": {
                "common": "mifepristone will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "mitapivat",
            "description": {
                "common": "mitapivat will decrease the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "mitotane",
            "description": {
                "common": "mitotane will decrease the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "mobocertinib",
            "description": {
                "common": "mobocertinib will decrease the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "modafinil",
            "description": {
                "common": "modafinil will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "nafcillin",
            "description": {
                "common": "nafcillin will decrease the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "nefazodone",
            "description": {
                "common": "nefazodone will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "nicardipine",
            "description": {
                "common": "nicardipine will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "nirmatrelvir/ritonavir",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "omeprazole",
            "description": {
                "common": "omeprazole will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "pantoprazole",
            "description": {
                "common": "pantoprazole will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "pentobarbital will decrease the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "pexidartinib",
            "description": {
                "common": "pexidartinib will decrease the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital will decrease the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin will decrease the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "posaconazole",
            "description": {
                "common": "posaconazole will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone will decrease the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "propofol",
            "description": {
                "common": "propofol will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "rabeprazole",
            "description": {
                "common": "rabeprazole will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "rifabutin",
            "description": {
                "common": "rifabutin will decrease the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "rifapentine",
            "description": {
                "common": "rifapentine will decrease the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "rucaparib",
            "description": {
                "common": "rucaparib will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "secobarbital",
            "description": {
                "common": "secobarbital will decrease the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "sertraline",
            "description": {
                "common": "sertraline will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "sitaxentan",
            "description": {
                "common": "sitaxentan will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "sotorasib",
            "description": {
                "common": "sotorasib will decrease the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "St John's Wort",
            "description": {
                "common": "St John's Wort will decrease the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "telotristat ethyl",
            "description": {
                "common": "telotristat ethyl will decrease the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ticlopidine",
            "description": {
                "common": "ticlopidine will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "tranylcypromine",
            "description": {
                "common": "tranylcypromine will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "triclabendazole",
            "description": {
                "common": "triclabendazole will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "voriconazole",
            "description": {
                "common": "voriconazole will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atenolol",
            "description": {
                "common": "atenolol, mavacamten.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Expect additive negative inotropic effects of mavacamten and other drugs that reduce cardiac contractility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "betaxolol",
            "description": {
                "common": "betaxolol, mavacamten.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Expect additive negative inotropic effects of mavacamten and other drugs that reduce cardiac contractility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bisoprolol",
            "description": {
                "common": "bisoprolol, mavacamten.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Expect additive negative inotropic effects of mavacamten and other drugs that reduce cardiac contractility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "celiprolol",
            "description": {
                "common": "celiprolol, mavacamten.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Expect additive negative inotropic effects of mavacamten and other drugs that reduce cardiac contractility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dienogest/estradiol valerate",
            "description": {
                "common": "mavacamten will decrease the level or effect of dienogest/estradiol valerate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Progestin and ethinyl estradiol are CYP3A4 substrates. Mavacamten may decrease systemic exposures of ethinyl estradiol and progestin, which may lead to contraceptive failure or an increase in breakthrough bleeding. Advise patients to use a contraceptive method that is not affected by CYP450 enzyme induction (eg, intrauterine system) or add nonhormonal contraception (eg, condoms) during coadministration and for 4 months after last mavacamten dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "diltiazem",
            "description": {
                "common": "diltiazem, mavacamten.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Expect additive negative inotropic effects of mavacamten and other drugs that reduce cardiac contractility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "disopyramide",
            "description": {
                "common": "disopyramide, mavacamten.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Expect additive negative inotropic effects of mavacamten and other drugs that reduce cardiac contractility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "drospirenone",
            "description": {
                "common": "mavacamten will decrease the level or effect of drospirenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Progestin and ethinyl estradiol are CYP3A4 substrates. Mavacamten may decrease systemic exposures of ethinyl estradiol and progestin, which may lead to contraceptive failure or an increase in breakthrough bleeding. Advise patients to use a contraceptive method that is not affected by CYP450 enzyme induction (eg, intrauterine system) or add nonhormonal contraception (eg, condoms) during coadministration and for 4 months after last mavacamten dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "elacestrant",
            "description": {
                "common": "mavacamten will decrease the level or effect of elacestrant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "esmolol",
            "description": {
                "common": "esmolol, mavacamten.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Expect additive negative inotropic effects of mavacamten and other drugs that reduce cardiac contractility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ethinylestradiol",
            "description": {
                "common": "mavacamten will decrease the level or effect of ethinylestradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Progestin and ethinyl estradiol are CYP3A4 substrates. Mavacamten may decrease systemic exposures of ethinyl estradiol and progestin, which may lead to contraceptive failure or an increase in breakthrough bleeding. Advise patients to use a contraceptive method that is not affected by CYP450 enzyme induction (eg, intrauterine system) or add nonhormonal contraception (eg, condoms) during coadministration and for 4 months after last mavacamten dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "etonogestrel",
            "description": {
                "common": "mavacamten will decrease the level or effect of etonogestrel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Progestin and ethinyl estradiol are CYP3A4 substrates. Mavacamten may decrease systemic exposures of ethinyl estradiol and progestin, which may lead to contraceptive failure or an increase in breakthrough bleeding. Advise patients to use a contraceptive method that is not affected by CYP450 enzyme induction (eg, intrauterine system) or add nonhormonal contraception (eg, condoms) during coadministration and for 4 months after last mavacamten dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lenacapavir",
            "description": {
                "common": "mavacamten will decrease the level or effect of lenacapavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of lenacapavir with moderate CYP3A4 inducers."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "leniolisib",
            "description": {
                "common": "mavacamten will decrease the level or effect of leniolisib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levonorgestrel intrauterine",
            "description": {
                "common": "mavacamten will decrease the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Progestin and ethinyl estradiol are CYP3A4 substrates. Mavacamten may decrease systemic exposures of ethinyl estradiol and progestin, which may lead to contraceptive failure or an increase in breakthrough bleeding. Advise patients to use a contraceptive method that is not affected by CYP450 enzyme induction (eg, intrauterine system) or add nonhormonal contraception (eg, condoms) during coadministration and for 4 months after last mavacamten dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levonorgestrel oral",
            "description": {
                "common": "mavacamten will decrease the level or effect of levonorgestrel oral by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Progestin and ethinyl estradiol are CYP3A4 substrates. Mavacamten may decrease systemic exposures of ethinyl estradiol and progestin, which may lead to contraceptive failure or an increase in breakthrough bleeding. Advise patients to use a contraceptive method that is not affected by CYP450 enzyme induction (eg, intrauterine system) or add nonhormonal contraception (eg, condoms) during coadministration and for 4 months after last mavacamten dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate",
            "description": {
                "common": "mavacamten will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Progestin and ethinyl estradiol are CYP3A4 substrates. Mavacamten may decrease systemic exposures of ethinyl estradiol and progestin, which may lead to contraceptive failure or an increase in breakthrough bleeding. Advise patients to use a contraceptive method that is not affected by CYP450 enzyme induction (eg, intrauterine system) or add nonhormonal contraception (eg, condoms) during coadministration and for 4 months after last mavacamten dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "medroxyprogesterone",
            "description": {
                "common": "mavacamten will decrease the level or effect of medroxyprogesterone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Progestin and ethinyl estradiol are CYP3A4 substrates. Mavacamten may decrease systemic exposures of ethinyl estradiol and progestin, which may lead to contraceptive failure or an increase in breakthrough bleeding. Advise patients to use a contraceptive method that is not affected by CYP450 enzyme induction (eg, intrauterine system) or add nonhormonal contraception (eg, condoms) during coadministration and for 4 months after last mavacamten dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "megestrol",
            "description": {
                "common": "mavacamten will decrease the level or effect of megestrol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Progestin and ethinyl estradiol are CYP3A4 substrates. Mavacamten may decrease systemic exposures of ethinyl estradiol and progestin, which may lead to contraceptive failure or an increase in breakthrough bleeding. Advise patients to use a contraceptive method that is not affected by CYP450 enzyme induction (eg, intrauterine system) or add nonhormonal contraception (eg, condoms) during coadministration and for 4 months after last mavacamten dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "metoprolol",
            "description": {
                "common": "metoprolol, mavacamten.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Expect additive negative inotropic effects of mavacamten and other drugs that reduce cardiac contractility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nadolol",
            "description": {
                "common": "nadolol, mavacamten.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Expect additive negative inotropic effects of mavacamten and other drugs that reduce cardiac contractility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nebivolol",
            "description": {
                "common": "nebivolol, mavacamten.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Expect additive negative inotropic effects of mavacamten and other drugs that reduce cardiac contractility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "norethindrone",
            "description": {
                "common": "mavacamten will decrease the level or effect of norethindrone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Progestin and ethinyl estradiol are CYP3A4 substrates. Mavacamten may decrease systemic exposures of ethinyl estradiol and progestin, which may lead to contraceptive failure or an increase in breakthrough bleeding. Advise patients to use a contraceptive method that is not affected by CYP450 enzyme induction (eg, intrauterine system) or add nonhormonal contraception (eg, condoms) during coadministration and for 4 months after last mavacamten dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "norethindrone acetate",
            "description": {
                "common": "mavacamten will decrease the level or effect of norethindrone acetate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Progestin and ethinyl estradiol are CYP3A4 substrates. Mavacamten may decrease systemic exposures of ethinyl estradiol and progestin, which may lead to contraceptive failure or an increase in breakthrough bleeding. Advise patients to use a contraceptive method that is not affected by CYP450 enzyme induction (eg, intrauterine system) or add nonhormonal contraception (eg, condoms) during coadministration and for 4 months after last mavacamten dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "norethindrone transdermal",
            "description": {
                "common": "mavacamten will decrease the level or effect of norethindrone transdermal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Progestin and ethinyl estradiol are CYP3A4 substrates. Mavacamten may decrease systemic exposures of ethinyl estradiol and progestin, which may lead to contraceptive failure or an increase in breakthrough bleeding. Advise patients to use a contraceptive method that is not affected by CYP450 enzyme induction (eg, intrauterine system) or add nonhormonal contraception (eg, condoms) during coadministration and for 4 months after last mavacamten dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "norgestrel",
            "description": {
                "common": "mavacamten will decrease the level or effect of norgestrel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Progestin and ethinyl estradiol are CYP3A4 substrates. Mavacamten may decrease systemic exposures of ethinyl estradiol and progestin, which may lead to contraceptive failure or an increase in breakthrough bleeding. Advise patients to use a contraceptive method that is not affected by CYP450 enzyme induction (eg, intrauterine system) or add nonhormonal contraception (eg, condoms) during coadministration and for 4 months after last mavacamten dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olutasidenib",
            "description": {
                "common": "mavacamten will decrease the level or effect of olutasidenib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong or moderate CYP3A inducers decrease olutasidenib (a CYP3A4 substrate) plasma concentrations and efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "omaveloxolone",
            "description": {
                "common": "mavacamten will decrease the level or effect of omaveloxolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "penbutolol",
            "description": {
                "common": "penbutolol, mavacamten.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Expect additive negative inotropic effects of mavacamten and other drugs that reduce cardiac contractility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "progesterone intravaginal gel",
            "description": {
                "common": "mavacamten will decrease the level or effect of progesterone intravaginal gel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Progestin and ethinyl estradiol are CYP3A4 substrates. Mavacamten may decrease systemic exposures of ethinyl estradiol and progestin, which may lead to contraceptive failure or an increase in breakthrough bleeding. Advise patients to use a contraceptive method that is not affected by CYP450 enzyme induction (eg, intrauterine system) or add nonhormonal contraception (eg, condoms) during coadministration and for 4 months after last mavacamten dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "progesterone micronized",
            "description": {
                "common": "mavacamten will decrease the level or effect of progesterone micronized by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Progestin and ethinyl estradiol are CYP3A4 substrates. Mavacamten may decrease systemic exposures of ethinyl estradiol and progestin, which may lead to contraceptive failure or an increase in breakthrough bleeding. Advise patients to use a contraceptive method that is not affected by CYP450 enzyme induction (eg, intrauterine system) or add nonhormonal contraception (eg, condoms) during coadministration and for 4 months after last mavacamten dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "propranolol",
            "description": {
                "common": "propranolol, mavacamten.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Expect additive negative inotropic effects of mavacamten and other drugs that reduce cardiac contractility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ranolazine",
            "description": {
                "common": "ranolazine, mavacamten.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Expect additive negative inotropic effects of mavacamten and other drugs that reduce cardiac contractility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "segesterone/ethinyl estradiol",
            "description": {
                "common": "mavacamten will decrease the level or effect of segesterone/ethinyl estradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Progestin and ethinyl estradiol are CYP3A4 substrates. Mavacamten may decrease systemic exposures of ethinyl estradiol and progestin, which may lead to contraceptive failure or an increase in breakthrough bleeding. Advise patients to use a contraceptive method that is not affected by CYP450 enzyme induction (eg, intrauterine system) or add nonhormonal contraception (eg, condoms) during coadministration and for 4 months after last mavacamten dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sotalol",
            "description": {
                "common": "sotalol, mavacamten.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Expect additive negative inotropic effects of mavacamten and other drugs that reduce cardiac contractility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "timolol",
            "description": {
                "common": "timolol, mavacamten.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Expect additive negative inotropic effects of mavacamten and other drugs that reduce cardiac contractility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "verapamil",
            "description": {
                "common": "verapamil, mavacamten.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Expect additive negative inotropic effects of mavacamten and other drugs that reduce cardiac contractility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vonoprazan",
            "description": {
                "common": "mavacamten will decrease the level or effect of vonoprazan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "zanubrutinib",
            "description": {
                "common": "mavacamten will decrease the level or effect of zanubrutinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of zanubrutinib (a CYP3A4 substrate) with moderate CYP3A4 inhibitors. If unavoidable, increase zanubrutinib dose to 320 mg PO BID. After discontinuing the CYP3A4 inhibitor, resume previous dose of zanubrutinib. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amiodarone",
            "description": {
                "common": "amiodarone will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amitriptyline",
            "description": {
                "common": "amitriptyline will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aprepitant",
            "description": {
                "common": "aprepitant will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azelastine",
            "description": {
                "common": "azelastine will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bicalutamide",
            "description": {
                "common": "bicalutamide will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brivaracetam",
            "description": {
                "common": "brivaracetam will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine",
            "description": {
                "common": "buprenorphine will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine buccal",
            "description": {
                "common": "buprenorphine buccal will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine transdermal",
            "description": {
                "common": "buprenorphine transdermal will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ceritinib",
            "description": {
                "common": "ceritinib will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cimetidine",
            "description": {
                "common": "cimetidine will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "citalopram",
            "description": {
                "common": "citalopram will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clotrimazole",
            "description": {
                "common": "clotrimazole will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clozapine",
            "description": {
                "common": "clozapine will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "crizotinib",
            "description": {
                "common": "crizotinib will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "cyclosporine will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam",
            "description": {
                "common": "diazepam will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diltiazem",
            "description": {
                "common": "diltiazem will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "divalproex sodium",
            "description": {
                "common": "divalproex sodium will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxycycline",
            "description": {
                "common": "doxycycline will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dronedarone",
            "description": {
                "common": "dronedarone will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "drospirenone",
            "description": {
                "common": "drospirenone will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elagolix",
            "description": {
                "common": "elagolix will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "entacapone",
            "description": {
                "common": "entacapone will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin base",
            "description": {
                "common": "erythromycin base will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin ethylsuccinate",
            "description": {
                "common": "erythromycin ethylsuccinate will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin lactobionate",
            "description": {
                "common": "erythromycin lactobionate will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin stearate",
            "description": {
                "common": "erythromycin stearate will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethotoin",
            "description": {
                "common": "ethotoin will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fedratinib",
            "description": {
                "common": "fedratinib will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "felbamate",
            "description": {
                "common": "felbamate will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenofibrate",
            "description": {
                "common": "fenofibrate will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenofibrate micronized",
            "description": {
                "common": "fenofibrate micronized will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenofibric acid",
            "description": {
                "common": "fenofibric acid will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "fexinidazole will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluconazole",
            "description": {
                "common": "fluconazole will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvoxamine",
            "description": {
                "common": "fluvoxamine will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosamprenavir",
            "description": {
                "common": "fosamprenavir will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosaprepitant",
            "description": {
                "common": "fosaprepitant will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fostamatinib",
            "description": {
                "common": "fostamatinib will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gefitinib",
            "description": {
                "common": "gefitinib will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haloperidol",
            "description": {
                "common": "haloperidol will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibrexafungerp",
            "description": {
                "common": "ibrexafungerp will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iloperidone",
            "description": {
                "common": "iloperidone will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imatinib",
            "description": {
                "common": "imatinib will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imipramine",
            "description": {
                "common": "imipramine will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indinavir",
            "description": {
                "common": "indinavir will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indomethacin",
            "description": {
                "common": "indomethacin will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "isavuconazonium sulfate will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isoniazid",
            "description": {
                "common": "isoniazid will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ivacaftor",
            "description": {
                "common": "ivacaftor will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lapatinib",
            "description": {
                "common": "lapatinib will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "larotrectinib",
            "description": {
                "common": "larotrectinib will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lefamulin",
            "description": {
                "common": "lefamulin will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lenacapavir",
            "description": {
                "common": "lenacapavir will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lenvatinib",
            "description": {
                "common": "lenvatinib will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "letermovir",
            "description": {
                "common": "letermovir will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "letrozole",
            "description": {
                "common": "letrozole will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "losartan",
            "description": {
                "common": "losartan will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mephobarbital",
            "description": {
                "common": "mephobarbital will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methimazole",
            "description": {
                "common": "methimazole will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methoxsalen",
            "description": {
                "common": "methoxsalen will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methsuximide",
            "description": {
                "common": "methsuximide will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metronidazole",
            "description": {
                "common": "metronidazole will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "netupitant/palonosetron",
            "description": {
                "common": "netupitant/palonosetron will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nilutamide",
            "description": {
                "common": "nilutamide will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olanzapine",
            "description": {
                "common": "olanzapine will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "orphenadrine",
            "description": {
                "common": "orphenadrine will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxcarbazepine",
            "description": {
                "common": "oxcarbazepine will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paroxetine",
            "description": {
                "common": "paroxetine will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentamidine",
            "description": {
                "common": "pentamidine will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pimozide",
            "description": {
                "common": "pimozide will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pioglitazone",
            "description": {
                "common": "pioglitazone will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "probenecid",
            "description": {
                "common": "probenecid will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "progesterone micronized",
            "description": {
                "common": "progesterone micronized will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinupristin/dalfopristin",
            "description": {
                "common": "quinupristin/dalfopristin will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ribociclib",
            "description": {
                "common": "ribociclib will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rosiglitazone",
            "description": {
                "common": "rosiglitazone will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "schisandra",
            "description": {
                "common": "schisandra will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "selegiline",
            "description": {
                "common": "selegiline will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sertraline",
            "description": {
                "common": "sertraline will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sildenafil",
            "description": {
                "common": "sildenafil will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sparsentan",
            "description": {
                "common": "sparsentan will decrease the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tecovirimat",
            "description": {
                "common": "tecovirimat will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "telmisartan",
            "description": {
                "common": "telmisartan will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tetracycline",
            "description": {
                "common": "tetracycline will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "topiramate",
            "description": {
                "common": "topiramate will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "torsemide",
            "description": {
                "common": "torsemide will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valproic acid",
            "description": {
                "common": "valproic acid will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vismodegib",
            "description": {
                "common": "vismodegib will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voxelotor",
            "description": {
                "common": "voxelotor will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Inititiation of moderate CYP3A4 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zafirlukast",
            "description": {
                "common": "zafirlukast will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Dizziness",
            "percent": "27"
        },
        {
            "name": "Syncope",
            "percent": "6"
        },
        {
            "name": "Reduced LVEF",
            "percent": "6"
        }
    ]
}